Reader-supported. We may earn a commission when you use our partner links. How we’re funded
Our take
Maximus stands out for explaining how ongoing support is supposed to work. I would weigh that against a dose-specific quote and an agreed follow-up plan, rather than choosing it because enrollment needs no lab visit.
What stands out
- Injection starting price published
- Home injection kit and priority shipping advertised
- Support guide separates clinical and delivery questions
What to weigh
- Starting price is not a fixed quote for every plan
- No required entry labs does not mean no later monitoring
- Dedicated product page excludes Alabama
A published injection price, with details still to settle
Maximus’s dedicated sermorelin page advertises injections from $199.99 per month, a home injection kit, and free priority shipping. Its wider peptide page qualifies pricing by dose and plan length. I would use the monthly figure to start a comparison, not as a final quote for every prescription.
The sales page also uses daily-price language that is not a substitute for the actual invoice. Request the amount payable today and at renewal, the term needed for that price, and the medication quantity. Those are the figures that determine whether the plan fits a budget.
I would not assume that a higher headline than another provider buys more medication or more useful care. The comparison needs both the prescribed supply and the services you expect to use.
An injection-only decision
The Maximus protocol overview describes sermorelin as a subcutaneous injection. We did not verify a current tablet or nasal offer. That makes the service a more focused comparison for someone already discussing injectable treatment with a clinician.
It also removes one reason some readers may prefer a different provider: there is no verified needle-free option in this reviewed protocol. If the administration routine is a deciding concern, raise it before payment rather than expecting a later switch.
For an injection, request the concentration, total amount, preparation, and pharmacy instructions. A home kit is a useful advertised inclusion, but it does not answer every handling question. Confirm who can help with a problem before the first shipment arrives. Our injection guide compares these practical details across providers.
No entry lab requirement is not a monitoring plan
The dedicated product page says lab testing and video evaluations are not required to qualify. Its refill guide separately explains that a clinician may request lab work, symptom check-ins, and treatment updates when appropriate.
I would read those statements together. A streamlined start does not establish that testing will never be needed or that an individual can skip clinical evaluation. Ask how your history and goals influence the initial assessment, and which findings would change the recommendation.
The useful question is what the clinician needs to know, not how quickly a purchase can be completed. If bloodwork is requested later, clarify its purpose, timing, and cost. Our IGF-1 guide explains why a biological measurement and a meaningful improvement are different things.
The support guide is a practical strength
Maximus distinguishes the prescribing clinician’s role from customer support. Its guide directs medication, symptom, and progress questions to clinician messaging in the patient portal; shipping, address, and account issues go to support.
That separation is useful. I would rather know where a question goes than see a broad promise of availability with no explanation. Still, the guide is a description of the intended process, not evidence that we measured response times or experienced the service.
Before joining, ask how follow-up is scheduled and how quickly a nonurgent clinical message is usually answered. If the service fits around work or travel, understand those expectations in advance. A delivery question and a treatment concern should not become the same queue simply because both arise after the order.
Refills, location, and delivery need planning
The dedicated sales page excludes Alabama. The support guide also ties prescribing to the patient’s physical location and the clinician’s licensing, so travel or a move can matter. Confirm current eligibility for your circumstances rather than relying on a national-looking storefront.
The same guide describes clinician-evaluated renewals and portal tracking. It directs patients with compromised shipments to support instead of using the medication. Those instructions give readers a clearer path when something goes wrong, though they do not guarantee a particular dispatch or replacement time.
I would also obtain the renewal charge and cancellation terms before paying; this review has not verified a sermorelin-specific refund promise. A refill process explains how care continues, but it does not fully explain the financial consequences of stopping.
My assessment of the overall offer
Maximus is worth investigating for readers who want an injection service with a relatively detailed explanation of ongoing support. I would put more weight on that practical information than on broad claims about recovery, appearance, or vitality.
The broader peptide page discusses both sermorelin and tesamorelin. Results attributed to another drug or population should not be carried across to your proposed prescription. Ask what supports the specific outcome being discussed and how the clinician would decide whether continuing makes sense.
Our October 2026 review uses the provider’s public offer and support pages. We have not enrolled, ordered medication, audited a pharmacy, or tested clinical outcomes. Compounded drugs are not FDA-approved. Compare the written quote with the other reviewed providers, and treat this assessment as help understanding the purchase rather than a medical endorsement.
Common questions
Does Maximus require labs to start sermorelin?
The dedicated sales page says lab testing and video evaluations are not required to qualify. Its refill guide says clinicians may request lab work when appropriate.
Is an oral option listed?
The sermorelin protocol overview describes subcutaneous injection only. We did not verify a current oral or nasal sermorelin offer from Maximus.
Explore Maximus
See the current offer and decide whether you want to start a consultation.
Visit MaximusReader-supported. We may earn a commission when you use our partner links. How we’re funded
Sources & further reading
Sources reviewed October 2026. Provider prices and terms may change.
- Maximus website
- Maximus support website
- FDA: Understanding the risks of compounded drugs
- Endocrine Society: Hormones and Aging scientific statement